Understanding Bioidentical Hormone Replacement Therapy BHRT and Its Benefits

What is BHRT? Understanding Bioidentical Hormone Replacement Therapy

Bioidentical Hormone Replacement Therapy (BHRT) is a treatment that supplements the natural hormones our bodies produce. As we age, hormone levels decline, leading to various health issues. By replacing these lost hormones, we can potentially prevent or correct age-related conditions.

Bioidentical hormones are not the same as synthetic hormones, which are derived from animals, like horses. Although animal hormones share some similarities with human hormones, they differ at the molecular level. These differences can have unknown effects on human health. Therefore, it is crucial to distinguish between synthetic and bioidentical hormones.

Bioidentical hormones are derived from natural sources, such as yams and soy. They are modified in laboratories to match the hormones produced by human endocrine glands. Many experts believe that bioidentical hormones are safer alternatives to synthetic options.

Despite common misconceptions about hormone therapies being harmful, extensive research supports the use of BHRT for treating and preventing chronic diseases. Replacing hormones that keep individuals healthy during their younger years may help delay or even reverse age-related issues like osteoporosis, dementia, heart disease, and weight gain.

Benefits of Hormone Replacement for Patients

1. Improves Cardiovascular Markers

A recent meta-analysis published in The Journal of North American Menopause Society in 2022 reviewed 29 randomized controlled trials involving nearly 2,000 perimenopausal and menopausal women. The study concluded that compounded hormones did not significantly alter lipid profiles or glucose metabolism, both of which are precursors to cardiovascular disease. The findings indicate that compounded hormones are effective and safe.

The literature highlights several cardiovascular benefits associated with hormone replacement therapy:

• Higher serum free testosterone levels are linked to a reduced risk of carotid atherosclerosis in diabetic men.

• Testosterone replacement therapy can effectively treat androgen deficiency in men, reducing fat mass, which is a contributor to cardiovascular disease.

• A year-long study demonstrated that combining testosterone replacement therapy with diet and exercise significantly improved metabolic syndrome markers in newly diagnosed diabetic men.

  
  

Hormone replacement therapy may also reduce the risk of coronary heart disease (CHD) in women. Even when started later in life, oral estradiol can decrease insulin resistance without inducing plaque rupture.

2. Prevents and Treats Osteoporosis

Osteoporosis is a significant health concern, especially among the elderly. Research indicates that between 14% and 58% of elderly individuals who suffer a hip fracture may die within a year. However, osteoporosis is not an inevitable part of aging.

Studies have shown that DHEA replacement can significantly increase hip bone mineral density in older adults. Furthermore, estrogen deficiency is a leading cause of osteoporosis in both men and women. Discontinuing estrogen can rapidly diminish hip fracture protection.

Osteoporosis also negatively affects dental health, increasing the risk of tooth loss and periodontitis. Research indicates that estrogen replacement users experience significantly less tooth loss compared to non-users.

3. Supports Mental and Brain Health

Hormonal balance is crucial for mental and brain health in both genders. For men with androgen deficiency, testosterone replacement therapy can address psychological effects. Research has shown that lower testosterone levels correlate with poorer cognitive function. Higher testosterone levels are associated with improved cognitive performance.

Additionally, estrogen-containing hormone therapy may protect younger women from Alzheimer's disease or reduce the risk of early onset. Using hormone therapy during early postmenopause may also lower Alzheimer's risk.

4. Treats Subclinical Hypothyroidism

Many patients suffer from subclinical hypothyroidism, often characterized by symptoms of low thyroid function despite normal TSH levels. This condition can lead to metabolic syndrome and other health issues.

Unlike conventional therapies that only address primary hypothyroidism, hormone replacement therapy can treat subclinical forms. This opens doors for patients who may not respond to standard treatments. Desiccated thyroid, which provides T4, T3, and other thyroid hormones, has shown promise in improving thyroid function.

5. Improves Sexual Function

Aging often leads to a decline in sexual function for both men and women due to hormonal changes. For women, approaching menopause can result in vaginal atrophy and dryness, making intimacy painful. Hormone replacement therapy can effectively treat these conditions.

A 2022 meta-analysis found that compounded vaginal androgen significantly improved symptoms of vaginal atrophy and enhanced female sexual function scores. For men, testosterone replacement therapy can address erectile dysfunction and decreased libido associated with androgen deficiency.

Thyroid deficiency can also lead to sexual dysfunction in men. Research indicates that treating underlying thyroid issues may benefit men suffering from erectile dysfunction.

Improve Your Health with BHRT

Bioidentical hormones offer numerous benefits for patients. The advantages discussed above provide a high-level overview of how hormones can positively impact various systems in the body, including the heart, skin, bones, sex organs, and brain.

In conclusion, BHRT presents a viable option for those looking to improve their health and well-being. It is essential to consult with a healthcare professional to determine if this therapy is suitable for individual needs.

Sources

1. Liu, PharmD, PhD, Yi, et al. Safety and Efficacy of Compounded Bioidentical Hormone Therapy (CBHT) in Perimenopausal and Postmenopausal Women: a Systematic Review and Meta-Analysis of Randomized Controlled Trials. Wolters Kluwer Health, Inc. on Behalf of The North American Menopause Society., 2022.

2. Fukui M, Kitagawa Y, Nakamura N, et al. Association between serum testosterone concentration and carotid atherosclerosis in men with type 2 diabetes. Diabetes care. 2003;26(6):1869-1873. doi:10.2337/diacare.26.6.1869

3. Winters SJ. Current status of testosterone replacement therapy in men. Archives of family medicine. 1999;8(3):257-263. doi:10.1001/archfami.8.3.257

4. Heufelder AE, Saad F, Bunck MC, Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. Journal of andrology. 2009;30(6):726-733. doi:10.2164/jandrol.108.007005

5. Zyriax BC, Algenstaedt P, Hess UF, Schöffauer M, Bamberger C, Boeing H, Windler E. Factors contributing to the risk of cardiovascular disease reflected by plasma adiponectin: data from the coronary risk factors for atherosclerosis in women (CORA) study. Atherosclerosis. 2008 Oct;200(2):403-9. doi: 10.1016/j.atherosclerosis.2007.12.033. Epub 2008 Feb 8. PMID: 18262188.

6. Karim R, Mack WJ, Lobo RA, et al. Determinants of the effect of estrogen on the progression of subclinical atherosclerosis: estrogen in the prevention of atherosclerosis trial. Menopause (10723714). 2005;12(4):366-373. doi:10.1097/01.gme.0000153934.76086.a4

7. Schnell, S., Friedman, S. M., Mendelson, D. A., Bingham, K. W., & Kates, S. L. (2010). The 1-year mortality of patients treated in a hip fracture program for elders. Geriatric orthopaedic surgery & rehabilitation, 1(1), 6–14. https://doi.org/10.1177/2151458510378105

8. Jankowski CM, Gozansky WS, Kittelson JM, Van Pelt RE, Schwartz RS, Kohrt WM. Increases in bone mineral density in response to oral dehydroepiandrosterone replacement in older adults appear to be mediated by serum estrogens. The Journal of clinical endocrinology and metabolism. 2008;93(12):4767-4773. doi:10.1210/jc.2007-2614

9. Carlsen CG, Soerensen TH, Eriksen EF. Prevalence of low serum estradiol levels in male osteoporosis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2000;11(8):697-701. doi:10.1007/s001980070068

10. Yates J, Barrett-Connor E, Barlas S, Chen Y, Miller PD, Siris ES. Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment. Obstetrics & Gynecology. 2004;103(3):440-446. doi:10.1097/01.aog.0000114986.14806.37

11. Paganini-Hill A. The benefits of estrogen replacement therapy on oral health. The Leisure World cohort. Archives of internal medicine. 1995;155(21):2325-2329. Accessed March 3, 2022.

12. Muller M, Aleman A, Grobbee DE, de Haan EHF, van der Schouw YT. Endogenous sex hormone levels and cognitive function in aging men: is there an optimal level? Neurology. 2005;64(5):866-871. doi:10.1212/01.wnl.0000153072.54068.e3

13. Henderson VW, Benke KS, Green RC, Cupples LA, Farrer LA. Postmenopausal hormone therapy and Alzheimer’s disease risk: interaction with age. Journal of neurology, neurosurgery, and psychiatry. 2005;76(1):103-105. doi:10.1136/jnnp.2003.024927

14. Zandi PP, Carlson MC, Plassman BL, et al. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA: Journal of the American Medical Association. 2002;288(17):2123-2129. doi:10.1001/jama.288.17.2123

15. Rivas AM, Lado-Abeal J. Thyroid hormone resistance and its management. Proc (Bayl Univ Med Cent). 2016;29(2):209-211. doi:10.1080/08998280.2016.11929421

16. Yang L, Lv X, Yue F, Wei D, Liu W, Zhang T. Subclinical hypothyroidism and the risk of metabolic syndrome: A meta-analysis of observational studies. Endocrine research. 2016;41(2):158-165. doi:10.3109/07435800.2015.1108332

17. Laclaustra M, Hurtado-Roca Y, Sendin M, et al. Lower-normal TSH is associated with better metabolic risk factors: A cross-sectional study on Spanish men. Nutrition, Metabolism & Cardiovascular Diseases. 2015;25(12):1095-1103. doi:10.1016/j.numecd.2015.09.007

18. Gullo D, Latina A, Frasca F, Le Moli R, Pellegriti G, Vigneri R. Levothyroxine monotherapy cannot guarantee euthyroidism in all athyreotic patients. PloS one. 2011;6(8):e22552. doi:10.1371/journal.pone.0022552

19. Wiersinga WM. THERAPY OF ENDOCRINE DISEASE: T4 + T3 combination therapy: is there a true effect? European journal of endocrinology. 2017;177(6):R287-R296. doi:10.1530/EJE-17-0645

20. Shifren JL, Davis SR, Moreau M, et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study. Menopause (10723714). 2006;13(5):770-779. doi:10.1097/01.gme.0000243567.32828.99

21. Veronelli A, Masu A, Ranieri R, Rognoni C, Laneri M, Pontiroli AE. Prevalence of erectile dysfunction in thyroid disorders: comparison with control subjects and with obese and diabetic patients. International journal of impotence research. 2006;18(1):111-114. doi:10.1038/sj.ijir.3901364

22. Gabrielson AT, Sartor RA, Hellstrom WJG. The Impact of Thyroid Disease on Sexual Dysfunction in Men and Women. Sexual medicine reviews. 2019;7(1):57-70. doi:10.1016/j.sxmr.2018.05.002

Credit/Source Worldlink Medical